Limits...
Low-dose polymyxin: an option for therapy of Gram-negative sepsis.

Harm S, Gabor F, Hartmann J - Innate Immun (2016)

Bottom Line: The formed LPS-PMB complex has lower inflammatory activity in blood, which results in highly reduced cytokine secretion.Furthermore, the combination of cytokine removal by adsorbent treatment with LPS inactivation by PMB dosage leads to strong suppression of inflammatory effects in blood in an in vitro model.Inactivation of endotoxins by low-dose intravenous PMB infusion or infusion into the extracorporeal circuit during blood purification can be applied to overcome the urgent need for endotoxin elimination not only in treatment of sepsis, but also in liver failure.

View Article: PubMed Central - PubMed

Affiliation: Department for Health Sciences and Biomedicine, Danube University Krems, Krems, Austria Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, Althanstraße 14, A-1090 Vienna, Austria stephan.harm@donau-uni.ac.at.

No MeSH data available.


Related in: MedlinePlus

PMB-dependent inactivation of endotoxins from P. aeruginosa in human plasma.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2 - License 3
getmorefigures.php?uid=PMC4834512&req=5

fig3-1753425916639120: PMB-dependent inactivation of endotoxins from P. aeruginosa in human plasma.

Mentions: To estimate the plasma level of PMB required to decrease the LPS activity to a certain level, the LPS inactivation in plasma was measured as a function of PMB concentration. At 0.5 ng/ml LPS, the ENC50 is 84 and 63 ng/ml for LPS from P. aeruginosa and E. coli, respectively. For 5 ng/ml LPS, the ENC50 is 219 and 381 ng/ml for LPS from P. aeruginosa and E. coli, respectively (Figures 3 and 4). The differences in the ENC50 for LPS from E. coli and P. aeruginosa, however, are not significant (t-test, P = 0.88 and P = 0.26, respectively) at both concentration levels.Figure 3.


Low-dose polymyxin: an option for therapy of Gram-negative sepsis.

Harm S, Gabor F, Hartmann J - Innate Immun (2016)

PMB-dependent inactivation of endotoxins from P. aeruginosa in human plasma.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2 - License 3
Show All Figures
getmorefigures.php?uid=PMC4834512&req=5

fig3-1753425916639120: PMB-dependent inactivation of endotoxins from P. aeruginosa in human plasma.
Mentions: To estimate the plasma level of PMB required to decrease the LPS activity to a certain level, the LPS inactivation in plasma was measured as a function of PMB concentration. At 0.5 ng/ml LPS, the ENC50 is 84 and 63 ng/ml for LPS from P. aeruginosa and E. coli, respectively. For 5 ng/ml LPS, the ENC50 is 219 and 381 ng/ml for LPS from P. aeruginosa and E. coli, respectively (Figures 3 and 4). The differences in the ENC50 for LPS from E. coli and P. aeruginosa, however, are not significant (t-test, P = 0.88 and P = 0.26, respectively) at both concentration levels.Figure 3.

Bottom Line: The formed LPS-PMB complex has lower inflammatory activity in blood, which results in highly reduced cytokine secretion.Furthermore, the combination of cytokine removal by adsorbent treatment with LPS inactivation by PMB dosage leads to strong suppression of inflammatory effects in blood in an in vitro model.Inactivation of endotoxins by low-dose intravenous PMB infusion or infusion into the extracorporeal circuit during blood purification can be applied to overcome the urgent need for endotoxin elimination not only in treatment of sepsis, but also in liver failure.

View Article: PubMed Central - PubMed

Affiliation: Department for Health Sciences and Biomedicine, Danube University Krems, Krems, Austria Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna, Althanstraße 14, A-1090 Vienna, Austria stephan.harm@donau-uni.ac.at.

No MeSH data available.


Related in: MedlinePlus